Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model

Figure 4

Combination treatment with PC61 mAb and mIL-12. Lung metastases were established in C57BL/6 mice via tail vein injection of D5lacZ cells. After 2 days, mice received intraperitoneal injections of 250 μg/0.5 ml PC61 mAb (PC61 only, Fusion + PC61 + ½ dose IL-12). On day 3, DC-tumor fusion cells (Fusion) were delivered intranodally. IL-12 was administered intraperitoneally daily for 4 days at 0.2 μg/0.5 ml (full dose) or 0.1 μg/0.5 ml (1/2 dose), respectively, starting on the day of vaccination. Mice were sacrificed after 21 days and lung metastases were enumerated.

Back to article page